February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
But financing sizes have grown by a similar amount on both sides of the Atlantic.
The first quarter of 2021 sets a new record, but the tide might be starting to turn.
First signals of efficacy, at doses thought to have been sub-therapeutic, send the Spac-listed group up 30%.